A recent clinical trial provided proof that pre-exposure prophylaxis (PrEP) gets

A recent clinical trial provided proof that pre-exposure prophylaxis (PrEP) gets the potential to avoid HIV an infection among individuals who inject medications (PWID). risk for HIV an infection. Keywords: PrEP PWID Acceptability HIV Risk Behavior Launch HIV pre-exposure prophylaxis (PrEP) provides demonstrated efficiency in stopping HIV infection in a number of randomized studies [1-3]. Lately the Bangkok Tenofovir Research a trial comprising 2 413 individuals who inject medications (PWID) in Bangkok Thailand shows that a program of once daily dental tenofovir reduced the chance of HIV acquisition by 49% [4]. There is evidence that much like other successful studies in nondrug users PrEP was most efficacious among PWID with high adherence to therapy. Nevertheless important public health questions remain including issues regarding the effectiveness implementation and overall feasibility of the rollout of PrEP to PWID in real-world settings. Initial evidence suggests that PrEP may be MLN9708 a cost-effective treatment among PWID [5] and although the difficulties and barriers to its implementation have been a topic of active argument MLN9708 [6-9] few studies have examined the acceptability of and willingness to use PrEP among drug users at risk for HIV [10]. In fact only two studies to date possess published data demonstrating willingness to use PrEP among a samples of PWID one among PWID in Ukraine [11] and more recently in Massachusetts United States (U.S.) [12]. In the study evaluating Ukrainian PWID data had been collected from an example of 128 energetic injectors 86 of whom had been “certainly” or “most likely” ready to consider PrEP [11]. General determination was low in the Massachusetts research with just 47% from the 351 PWID noting that they might be ready to consider PrEP. Additional data over the acceptability of PrEP among PWID are vital to estimation the percentage that are prepared to take part in PrEP regimens and could also inform open public health efforts to MLN9708 recognize the sociodemographic features and behaviors connected with higher approval of PrEP as well as provide early indications of the obstacles to high adherence. The Downtown Eastside (DTES) community of Vancouver United kingdom Columbia houses around 5 0 PWID and may be the middle of an adult HIV epidemic [13]. Many PWID in the DTES community get access to a wide array of evidence-based HIV prevention programs including: a supervised injection facility needle and syringe exchange programs opioid substitution therapy (OST) and a large-scale treatment as prevention system [14 15 Even though incidence of HIV among PWID in Vancouver offers declined significantly over the past decade [16 17 many HIV bad drug users remain at elevated risk for illness and thus may be eligible for PrEP under future Health Canada recommendations (in May 2014 the U.S. CDC released recommendations recommending the use of PrEP among MLN9708 PWID at considerable risk for HIV acquisition) [18]. Given the paucity of data available to inform PrEP implementation attempts for PWID and since medicines use patterns and HIV risk MLN9708 behaviours of PWID vary considerably across different settings [19-23] the objective of this study was to describe the willingness of PWID to use PrEP in a highly resourced North American setting. METHODS Participants were injection drug users enrolled in the Vancouver Injection Drug Users Study (VIDUS) an open prospective community-recruited cohort of HIV bad PWID that began in 1996. Individuals were eligible to participate in VIDUS if they resided in the Greater Vancouver region were actively injecting medicines at enrollment (self-reported injection drug use in the past month verified by exam for injection stigmata) and were able to provide educated MLN9708 consent. Given the period of enrollment for many VIDUS cohort users not all participants for this specific study had recently injected medicines. Between December 2012 and could 2013 543 HIV detrimental VIDUS participants finished a supplemental questionnaire eliciting details regarding understanding of and determination to make use of PrEP if Rabbit Polyclonal to CLIP1. it had been made available in the foreseeable future (HIV position was ascertained by antibody assay from bloodstream samples drawn through the research go to). Before administration from the study participants had been asked if they had heard about pre-exposure prophylaxis or “PrEP” for HIV avoidance. All participants irrespective of prior PrEP understanding were after that briefly informed by educated nurses about the function of PrEP in avoiding the acquisition of HIV. The nurses up to date participants that.